iihny posts
FeedPosted Feb 2nd 2009 1:00PM by Eric Buscemi (RSS feed)
Filed under: Analyst reports, Analyst upgrades and downgrades, Pfizer (PFE), Charles Schwab Corp (SCHW), NYSE Euronext (NYX), Analyst initiations, Akamai Technologies (AKAM), SanDisk Corp (SNDK)
.gif)
Analyst upgrades:
- Merriman upgraded shares of Akamai (NASDAQ:AKAM) to Buy from Neutral as they believe consensus expectations are now realistic and already reflect macro headwinds. Merriman also thinks the company's cost reductions could generate upside to EPS estimates.
- JP Morgan upgraded Novo Nordisk (NYSE:NVO) to Overweight from Neutral on expectations the company's diabetes drug will gain U.S. approval.
- Credit Suisse upgraded Pfizer (NYSE:PFE) to Outperform from Neutral and raised their target to $20 from $19 citing the merits of the Wyeth (WYE) deal and valuation.
- Quality Systems (NASDAQ:QSII) was upgraded to Buy from Neutral at Piper Jaffray.
- Parexel (NASDAQ:PRXL) was raised to Outperform from Market Perform at Wachovia.
- Ferro (NYSE:FOE) was upgraded at KeyBanc to Hold from Underweight.
Continue reading Analyst upgrades, downgrades and initiations: AKAM, PFE, NYX, SCHW, SNDK
Why isn't Bank of America updating its shareholders on CEO situation?
Before the bell: Futures sharply lower on Dubai's debt problems
Will Rich Ross really have a positive impact on Disney's movie operations?
